Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation
Rónán Daly Gavin Blackburn Manikhandan Mudaliar Karl Burgess Anne Stirling Duncan Porter Iain McInnes Michael P. Barrett James Dale
, 2019-7-8
Karl Burgess
Burgess Karl
ORCID: 0000-0002-0881-715X
Enhanced acylcarnitine annotation in high-resolution mass spectrometry data: fragmentation analysis for the classification and annotation of acylcarnitines. 10.3389/fbioe.2015.00026
Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism. 10.1016/j.ijpddr.2013.11.002
Strategies to dissect parasite proteomes. 10.1017/S0031182011002368
Recent advances in liquid and gas chromatography methodology for extending coverage of the metabolome 10.1016/j.copbio.2016.09.006
A novel targeted/untargeted GC-Orbitrap metabolomics methodology applied to Candida albicans and Staphylococcus aureus biofilms 10.1007/s11306-016-1134-2
MetaboCraft: building a Minecraft plugin for metabolomics 10.1093/bioinformatics/bty102
Minimally-destructive atmospheric ionisation mass spectrometry authenticates authorship of historical manuscripts 10.1038/s41598-018-28810-2
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation 10.1101/19001594
Changing environments and genetic variation: natural variation in inbreeding does not compromise short-term physiological responses 10.1098/rspb.2019.2109
Functional colour genes and signals of selection in colour‐polymorphic salamanders 10.1111/mec.15411
Decomposing metabolite set activity levels with PALS 10.1101/2020.06.07.138974
Schistosoma haematobium infection is associated with alterations in energy and purine-related metabolism in preschool-aged children 10.1371/journal.pntd.0008866
Ranking Metabolite Sets by Their Activity Levels 10.3390/metabo11020103
Duncan Porter
Porter Duncan
ORCID: 0000-0001-8481-5204
Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers 10.1155/2013/764518
Optimising the strategy of care in early rheumatoid arthritis 10.1016/j.berh.2009.11.009
Oxygen cost of walking, physical activity, and sedentary behaviours in rheumatoid arthritis 10.3109/03009742.2013.802009
Rheumatological complications of sickle cell disease 10.1016/S0950-3579(05)80280-8
Symmetrical polyarthritis. Time for treatment targets in rheumatoid arthritis. 10.1136/bmj.c4170
Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: Long-term safety and survival using prospective, observational data 10.1093/rheumatology/ket333
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: Results from the double-blind placebo-controlled MASCOT study 10.1136/ard.2006.057133
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis 10.1136/annrheumdis-2012-202450
Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies 10.1002/art.22808
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register 10.1002/art.22809
Myocrisin-mediated oxidative stress 10.1016/S0009-8981(97)00170-8
Bronchiolitis obliterans in systemic lupus erythematosus 10.1136/ard.51.7.927-b
Trials in rheumatoid arthritis: Choosing the right outcome measures - Comment on the article by Felson et al 10.1136/ard.2008.094805
Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis 10.1136/annrheumdis-2013-204851
DAS28 and rheumatoid arthritis: The need for standardization 10.1002/msc.218
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register 10.1136/annrheumdis-2011-200622
Pneumocystis Carinii infection complicating cytotoxic therapy in two patients with lymphopenia, but a normal total white cell count 10.1093/rheumatology/31.1.71
Identification of urinary peptide biomarkers associated with rheumatoid arthritis 10.1371/journal.pone.0104625
Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial 10.1136/ard.2003.014050
Functionally optimized orthoses for early rheumatoid arthritis foot disease: A study of mechanisms and patient experience 10.1002/acr.22060
Glucocorticoids and joint destruction in rheumatoid arthritis [2] 10.1056/NEJM199512073332314
Triple therapy in early active rheumatoid arthritis: A randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies 10.1002/art.23449
The 'natural' history of active rheumatoid arthritis over 3-6 months-an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo 10.1093/rheumatology/32.6.463
Uk cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug 10.1185/03007990802321683
Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity 10.1093/rheumatology/kep242
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial 10.1016/S0140-6736(04)16676-2
The use of sulphasalazine as a disease modifying antirheumatic drug 10.1016/S0950-3579(05)80006-8
Terbinafine as a cause of cutaneous lupus erythematosus [6] 10.1093/rheumatology/keg440
A double blind controlled trial of the addition of hydroxychloroquine (Hcq) or placebo (pbo) to patients with a suboptimal response after 6 months of im gold 10.1093/rheumatology/XXX.suppl_2.137
Acute renal failure complicating HELLP syndrome, SLE and anti-phospholipid syndrome: Successful outcome using plasma exchange therapy 10.1191/0961203303lu378xx
Non-Hodgkin's lymphoma in rheumatoid arthritis 10.1136/ard.50.5.275
Outcome of second line therapy in rheumatoid arthritis 10.1136/ard.53.12.812
Targeting ultrasound remission in early rheumatoid arthritis: The results of the TaSER study, a randomised clinical trial 10.1136/annrheumdis-2015-208941
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register 10.1002/acr.20129
Late Ebola virus relapse causing meningoencephalitis: a case report. 10.1016/S0140-6736(16)30386-5
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. 10.1016/S0140-6736(16)00380-9
Predicting functional disability: One year results from the Scottish Early Rheumatoid Arthritis Inception Cohort. 10.1002/art.39627
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. 10.1186/s12967-018-1387-9
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. 10.1136/annrheumdis-2017-212256
Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration. 10.1038/nrrheum.2018.6
The RA-MAP Consortium: a working model for academia-industry collaboration. 10.1038/nrrheum.2017.200
Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. 10.1136/annrheumdis-2017-211708
MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. 10.1038/ncomms15877
Editorial: Choosing New Targets for Rheumatoid Arthritis Therapeutics: Too Interesting to Fail? 10.1002/art.40082
Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. 10.1038/srep40473
Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. 10.1136/annrheumdis-2016-209784
The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. 10.1186/s12891-016-1318-y
Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. 10.1136/annrheumdis-2016-209389
Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants. 10.1136/rmdopen-2016-000267
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation 10.1101/19001594
Classification criteria: time for a rethink? 10.1136/annrheumdis-2020-217769
James Dale
Dale James
ORCID: 0000-0003-4769-8234
The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank 10.1186/s12891-016-1318-y
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation 10.1101/19001594
Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage Activation 10.3390/metabo10060241
Scottish rheumatology sonography course: five-year experience of delivering a mentorship-model rheumatology ultrasound training programme accredited by the consortium for the accreditation of sonographic education 10.1177/0036933020983569
Mike Barrett
Barrett Mike
ORCID: 0000-0001-9447-3519
Why aren't we doing more to safeguard vulnerable adults from thermal injuries? 10.1016/j.neurobiola.08.018
Vacuolar ATPase depletion affects mitochondrial ATPase function, kinetoplast dependency, and drug sensitivity in trypanosomes. 10.1073/pnas.1505411112
Host reticulocytes provide metabolic reservoirs that can be exploited by malaria parasites. 10.1371/journal.ppat.1004882
An Atypical Mitochondrial Carrier That Mediates Drug Action in Trypanosoma brucei. 10.1371/journal.ppat.1004875
Intravital imaging of a massive lymphocyte response in the cortical dura of mice after peripheral infection by trypanosomes. 10.1371/journal.pntd.0003714
Probing the metabolic network in bloodstream-form Trypanosoma brucei using untargeted metabolomics with stable isotope labelled glucose. 10.1371/journal.ppat.1004689
Enhanced acylcarnitine annotation in high-resolution mass spectrometry data: fragmentation analysis for the classification and annotation of acylcarnitines. 10.3389/fbioe.2015.00026
Bestatin induces specific changes in Trypanosoma cruzi dipeptide pool. 10.1128/AAC.05046-14
Crystal structure of an arginase-like protein from Trypanosoma brucei that evolved without a binuclear manganese cluster. 10.1021/bi501366a
Potent trypanocidal curcumin analogs bearing a monoenone linker motif act on trypanosoma brucei by forming an adduct with trypanothione. 10.1124/mol.114.096016
TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei. 10.1093/nar/gku944
Metabolomic-based strategies for anti-parasite drug discovery. 10.1177/1087057114551519
Structure-based design and synthesis of antiparasitic pyrrolopyrimidines targeting pteridine reductase 1. 10.1021/jm500483b
BCKDH: the missing link in apicomplexan mitochondrial metabolism is required for full virulence of Toxoplasma gondii and Plasmodium berghei. 10.1371/journal.ppat.1004263
Trypanosoma brucei: meet the system. 10.1016/j.mib.2014.06.007
Characterization of a melamino nitroheterocycle as a potential lead for the treatment of human african trypanosomiasis. 10.1128/AAC.01449-13
Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. 10.1371/journal.pntd.0002844
Rare-cell enrichment by a rapid, label-free, ultrasonic isopycnic technique for medical diagnostics. 10.1002/anie.201310401
Stable isotope-labeling studies in metabolomics: new insights into structure and dynamics of metabolic networks. 10.4155/bio.13.348
Emerging paradigms in anti-infective drug design. 10.1017/S0031182013001224
The silicon trypanosome: a test case of iterative model extension in systems biology. 10.1016/B978-0-12-800143-1.00003-8
Shape-dependent optoelectronic cell lysis. 10.1002/anie.201307751
Green fluorescent diamidines as diagnostic probes for trypanosomes. 10.1128/AAC.02024-13
Handling uncertainty in dynamic models: the pentose phosphate pathway in Trypanosoma brucei. 10.1371/journal.pcbi.1003371
Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. 10.1093/jac/dkt442
A Trypanosoma brucei kinesin heavy chain promotes parasite growth by triggering host arginase activity. 10.1371/journal.ppat.1003731
The threonine degradation pathway of the Trypanosoma brucei procyclic form: the main carbon source for lipid biosynthesis is under metabolic control. 10.1111/mmi.12351
In vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasis. 10.1371/journal.pntd.0002384
Explicit consideration of topological and parameter uncertainty gives new insights into a well-established model of glycolysis. 10.1111/febs.12436
Determination of antiprotozoal drug mechanisms by metabolomics approaches. 10.1017/S0031182013000814
Metabolite-dependent regulation of gene expression in Trypanosoma brucei. 10.1111/mmi.12243
Metabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei. 10.1128/AAC.00044-13
Minor groove binders as anti-infective agents. 10.1016/j.pharmthera.2013.03.002
Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake. 10.1016/j.ijpddr.2013.01.004
The 2-methylcitrate cycle is implicated in the detoxification of propionate in Toxoplasma gondii. 10.1111/mmi.12139
mzMatch-ISO: an R tool for the annotation and relative quantification of isotope-labelled mass spectrometry data. 10.1093/bioinformatics/bts674
Management of trypanosomiasis and leishmaniasis. 10.1093/bmb/lds031
Counterflow dielectrophoresis for trypanosome enrichment and detection in blood. 10.1038/srep00775
Stable isotope-assisted metabolomics for network-wide metabolic pathway elucidation. 10.1021/ac3018795
Identification and development of the 1,4-benzodiazepin-2-one and quinazoline-2,4-dione scaffolds as submicromolar inhibitors of HAT. 10.1016/j.bmc.2012.08.049
Synthesis and biological evaluation of CTP synthetase inhibitors as potential agents for the treatment of African trypanosomiasis. 10.1002/cmdc.201200304
Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. 10.1073/pnas.1202885109
Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei. 10.1371/journal.pntd.0001618
IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data. 10.1093/bioinformatics/bts069
Evaluation of coupling reversed phase, aqueous normal phase, and hydrophilic interaction liquid chromatography with Orbitrap mass spectrometry for metabolomic studies of human urine. 10.1021/ac2030738
Dynamic modelling under uncertainty: the case of Trypanosoma brucei energy metabolism. 10.1371/journal.pcbi.1002352
A comparison of leg length and femoral offset discrepancies in hip resurfacing, large head metal-on- metal and conventional total hip replacement: a case series. 10.1186/1749-799X-6-65
Semi-targeted analysis of metabolites using capillary-flow ion chromatography coupled to high-resolution mass spectrometry. 10.1002/rcm.5247
Pathos: a web facility that uses metabolic maps to display experimental changes in metabolites identified by mass spectrometry. 10.1002/rcm.5245
Toward global metabolomics analysis with hydrophilic interaction liquid chromatography-mass spectrometry: improved metabolite identification by retention time prediction. 10.1021/ac2021823
Metabolomic analysis of trypanosomatid protozoa. 10.1016/j.molbiopara.2011.10.003
Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. 10.1371/journal.pntd.0001308
Drug resistance in human African trypanosomiasis. 10.2217/fmb.11.88
Development of novel drugs for human African trypanosomiasis. 10.2217/fmb.11.44
Transketolase in Trypanosoma brucei. 10.1016/j.molbiopara.2011.04.006
The diamidine diminazene aceturate is a substrate for the high-affinity pentamidine transporter: implications for the development of high resistance levels in trypanosomes. 10.1124/mol.111.071555
Matrix-free mass spectrometric imaging using laser desorption ionisation Fourier transform ion cyclotron resonance mass spectrometry. 10.1002/rcm.4939
Trypanocidal furamidine analogues: influence of pyridine nitrogens on trypanocidal activity, transport kinetics, and resistance patterns. 10.1128/AAC.01551-10
A glucose transporter can mediate ribose uptake.: DEFINITION OF RESIDUES THAT CONFER SUBSTRATE SPECIFICITY IN A SUGAR TRANSPORTER. 10.1074/jbc.A110.106815
Separation of parasites from human blood using deterministic lateral displacement. 10.1039/c0lc00560f
Synthesis and biological evaluation of 1,4-benzodiazepin-2-ones with antitrypanosomal activity. 10.1016/j.bmc.2011.01.010
Synthesis and in vitro/in vivo evaluation of the antitrypanosomal activity of 3-bromoacivicin, a potent CTP synthetase inhibitor. 10.1002/cmdc.201000417
The 6-phosphogluconate dehydrogenase of Leishmania (Leishmania) mexicana: gene characterization and protein structure prediction. 10.1159/000320697
Potential new drugs for human African trypanosomiasis: some progress at last. 10.1097/QCO.0b013e32833f9fd0
A molecular mechanism for eflornithine resistance in African trypanosomes. 10.1371/journal.ppat.1001204
Aryl phosphoramidates of 5-phospho erythronohydroxamic acid, a new class of potent trypanocidal compounds. 10.1021/jm1004754
A fluorescence-based assay for the uptake of CPD0801 (DB829) by African trypanosomes. 10.1016/j.molbiopara.2010.07.002
A glucose transporter can mediate ribose uptake: definition of residues that confer substrate specificity in a sugar transporter. 10.1074/jbc.M110.106815
Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif. 10.1016/j.bmcl.2010.06.070
Multiple roles of proline transport and metabolism in trypanosomatids. 10.2741/3931
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. 10.1016/j.bmc.2010.05.077
The silicon trypanosome. 10.1017/S0031182010000466
MetExplore: a web server to link metabolomic experiments and genome-scale metabolic networks. 10.1093/nar/gkq312
Metabolomic systems biology of trypanosomes. 10.1017/S003118201000017X
Use of reconstituted metabolic networks to assist in metabolomic data visualization and mining. 10.1007/s11306-009-0196-9
Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. 10.1128/EC.00200-09
Predictive computational models of substrate binding by a nucleoside transporter. 10.1074/jbc.M109.049726
Genotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawal. 10.1371/journal.pntd.0000523
The Toxoplasma gondii plastid replication and repair enzyme complex, PREX. 10.1017/S0031182009006027
Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. 10.1093/brain/awp074
Unsaturated Mannich bases active against multidrug-resistant Trypanosoma brucei brucei strains. 10.1002/cmdc.200800360
Targeted delivery of compounds to Trypanosoma brucei using the melamine motif. 10.1016/j.bmc.2009.01.058
Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites. 10.1039/b813394h
Paromomycin: uptake and resistance in Leishmania donovani. 10.1016/j.molbiopara.2008.12.007
The natural progression of Gambiense sleeping sickness: what is the evidence? 10.1371/journal.pntd.0000303
Increasing the mass accuracy of high-resolution LC-MS data using background ions: a case study on the LTQ-Orbitrap. 10.1002/pmic.200800314
Synthesis of novel benzamidine- and guanidine-derived polyazamacrocycles: Selective anti-protozoal activity for human African trypanosomiasis. 10.1016/j.bmcl.2008.09.047
Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. 10.1128/AAC.01450-07
Metabolomic profiling using Orbitrap Fourier transform mass spectrometry with hydrophilic interaction chromatography: a method with wide applicability to analysis of biomolecules. 10.1002/rcm.3564
Glucose-induced remodeling of intermediary and energy metabolism in procyclic Trypanosoma brucei. 10.1074/jbc.M709592200
N-acetyl D-glucosamine stimulates growth in procyclic forms of Trypanosoma brucei by inducing a metabolic shift. 10.1017/S0031182008004241
African sleeping sickness. 10.1136/bmj.39505.490544.BE
Synthesis and anti-protozoal activity of C2-substituted polyazamacrocycles. 10.1016/j.bmcl.2008.02.037
New surveyor tools for charting microbial metabolic maps. 10.1038/nrmicro1797
MetaNetter: inference and visualization of high-resolution metabolomic networks. 10.1093/bioinformatics/btm536
A new erythrose 4-phosphate dehydrogenase coupled assay for transketolase. 10.1016/j.jprot.2007.11.002
Synthesis, characterisation and anti-protozoal activity of carbamate-derived polyazamacrocycles. 10.1039/b710487a
McArthur revisited: fluorescence microscopes for field diagnostics. 10.1016/
Synthesis and biological evaluation of phosphate prodrugs of 4-phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphogluconate dehydrogenase. 10.1002/cmdc.200700040
Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. 10.1038/sj.bjp.0707354
Molecular cloning, expression and characterization of ribokinase of Leishmania major. 10.1111/j.1745-7270.2007.00298.x
Crystal structures of a bacterial 6-phosphogluconate dehydrogenase reveal aspects of specificity, mechanism and mode of inhibition by analogues of high-energy reaction intermediates. 10.1111/j.1742-4658.2006.05585.x
Precision mapping of the metabolome. 10.1016/j.tibtech.2006.10.006
Roles for the Trypanosoma brucei P2 transporter in DB75 uptake and resistance. 10.1124/mol.106.024653
DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in vivo antitrypanosomal activity. 10.1021/jm060295c
The rise and fall of sleeping sickness. 10.1016/S0140-6736(06)68591-7
Targeting of toxic compounds to the trypanosome's interior. 10.1016/S0065-308X(06)63002-9
Interaction of monobenzamidine-linked trypanocides with the Trypanosoma brucei P2 aminopurine transporter. 10.1128/AAC.49.12.5169-5171.2005
Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. 10.1016/j.molbiopara.2005.08.016
Chemotherapy of trypanosomiases and leishmaniasis. 10.1016/
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. 10.1021/jm050177+
Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. 10.1016/S0140-6736(05)66793-1
The plastidic DNA replication enzyme complex of Plasmodium falciparum. 10.1016/j.molbiopara.2005.02.002
Energy generation in insect stages of Trypanosoma brucei: metabolism in flux. 10.1016/
Proline metabolism in procyclic Trypanosoma brucei is down-regulated in the presence of glucose. 10.1074/jbc.M414274200
Plasmodium interspersed repeats: the major multigene superfamily of malaria parasites. 10.1093/nar/gkh907
6-phosphogluconate dehydrogenase: a target for drugs in African trypanosomes. 10.2174/0929867043364441
Selective inhibition of Trypanosoma brucei 6-phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues. 10.1021/jm031066i
Trypanocidal activity of melamine-based nitroheterocycles. 10.1128/AAC.48.5.1733-1738.2004
The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes. 10.1128/AAC.48.5.1515-1519.2004
Interaction of substituted hexose analogues with the Trypanosoma brucei hexose transporter. 10.1016/j.bcp.2003.09.005
The trypanosomiases. 10.1016/S0140-6736(03)14694-6
Activity of megazol, a trypanocidal nitroimidazole, is associated with DNA damage. 10.1128/AAC.47.10.3368-3370.2003
Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. 10.1128/EC.2.5.1003-1008.2003
Pentose phosphate metabolism in Leishmania mexicana. 10.1016/S0166-6851(03)00173-7
Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. 10.1016/S0968-0896(03)00191-3
Antiplasmodial activity of a series of 1,3,5-triazine-substituted polyamines. 10.1093/jac/dkg307
Waking up to sleeping sickness. 10.1016/S1471-4922(03)00055-2
Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. 10.1016/S1471-4922(03)00069-2
Cloning, heterologous expression, and in situ characterization of the first high affinity nucleobase transporter from a protozoan. 10.1074/jbc.M301252200
Genetic characterization of glucose transporter function in Leishmania mexicana. 10.1073/pnas.0630165100
Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. 10.1128/AAC.46.12.3731-3738.2002
Polymorphism among alleles of the 6-phosphogluconate dehydrogenase gene from Leishmania major and Leishmania tropica. 10.1016/S0166-6851(02)00213-X
Perspectives for new drugs against trypanosomiasis and leishmaniasis. 10.2174/1568026024607427
Sleeping sickness and the brain. 10.1007/s00018-002-8472-0
A large gene family for putative variant antigens shared by human and rodent malaria parasites. 10.1098/rspb.2001.1903
Chemotherapy of human African trypanosomiasis. 10.2174/1381612023396159
Synthesis and biological evaluation of s-triazine substituted polyamines as potential new anti-trypanosomal drugs. 10.1021/jm010854+
Life in vacuoles--nutrient acquisition by Leishmania amastigotes. 10.1016/S0020-7519(01)00259-4
Veterinary link to drug resistance in human African trypanosomiasis? 10.1016/S0140-6736(01)05817-2
Selective inhibition of 6-phosphogluconate dehydrogenase from Trypanosoma brucei. 10.1023/A:1011196508214
Gene discovery in Plasmodium chabaudi by genome survey sequencing. 10.1016/S0166-6851(01)00224-9
Uptake and mode of action of drugs used against sleeping sickness. 10.1016/S0006-2952(00)00477-9
Transport of methionine in Trypanosoma brucei brucei. 10.1016/S0166-6851(00)00321-2
Drug uptake via nutrient transporters in Trypanosoma brucei. 10.1046/j.1365-2672.2000.01168.x
The structure-function relationship of functionally distinct but structurally similar hexose transporters from Trypanosoma congolense. 10.1046/j.1432-1327.2000.01543.x
Putrescine and spermidine transport in Leishmania. 10.1016/S0166-6851(00)00234-6
Uptake of the nitroimidazole drug megazol by African trypanosomes. 10.1016/S0006-2952(99)00368-8
Further evidence for a link between melarsoprol resistance and P2 transporter function in African trypanosomes. 10.1016/S0166-6851(99)00206-6
Anti-sleeping sickness drugs and cancer chemotherapy. 10.1016/S0169-4758(99)01560-4
A drug resistance determinant in Trypanosoma brucei. 10.1016/S0966-842X(99)01643-1
Structure and function of facilitative sugar transporters. 10.1016/S0955-0674(99)80072-6
The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. 10.1016/S0169-4758(99)01414-3
The fall and rise of sleeping sickness. 10.1016/S0140-6736(98)00416-4
Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. 10.1016/S0966-842X(98)01433-4
Trypanosomiasis and leishmaniasis: between the idea and the reality of control. 10.1016/S0169-4758(98)01374-X
6-Phosphogluconate dehydrogenase from Lactococcus lactis: a role for arginine residues in binding substrate and coenzyme. 10.1042/0264-6021:3380055
Affinity chromatography using trypanocidal arsenical drugs identifies a specific interaction between glycerol-3-phosphate dehydrogenase from Trypanosoma brucei and Cymelarsan. 10.1046/j.1432-1327.1999.00048.x
6-Phosphogluconate dehydrogenase: the mechanism of action investigated by a comparison of the enzyme from different species. 10.1016/S0167-4838(98)00222-2
Sugar transporters from bacteria, parasites and mammals: structure-activity relationships. 10.1016/S0968-0004(98)01326-7
Crystallization and preliminary X-ray diffraction studies of 6-phosphogluconate dehydrogenase from Lactococcus lactis. 10.1107/S0907444998004909
A 2.8 A resolution structure of 6-phosphogluconate dehydrogenase from the protozoan parasite Trypanosoma brucei: comparison with the sheep enzyme accounts for differences in activity with coenzyme and substrate analogues. 10.1006/jmbi.1998.2059
Cloning and characterization of the two enzymes responsible for trypanothione biosynthesis in Crithidia fasciculata. 10.1074/jbc.273.31.19383
An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. 10.1016/S0960-894X(98)00095-X
Trypanosome glucose transporters. 10.1016/S0166-6851(97)00192-8
A single locus minisatellite sequence which distinguishes between Trypanosoma brucei isolates. 10.1016/S0166-6851(97)02832-6
The pentose phosphate pathway and parasitic protozoa. 10.1016/S0169-4758(96)10075-2
6-Phosphogluconate dehydrogenase from Trypanosoma brucei. Kinetic analysis and inhibition by trypanocidal drugs. 10.1111/j.1432-1033.1996.0592h.x
A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. 10.1016/0166-6851(95)00120-P
Characterization of glucose transport and cloning of a hexose transporter gene in Trypanosoma cruzi. 10.1073/pnas.91.17.8278
Overexpression in Escherichia coli and purification of the 6-phosphogluconate dehydrogenase of Trypanosoma brucei. 10.1006/prep.1994.1006
Preliminary crystallographic study of 6-phosphogluconate dehydrogenase from Trypanosoma brucei. 10.1006/jmbi.1993.1510
A 6-phosphogluconate dehydrogenase gene from Trypanosoma brucei. 10.1016/0166-6851(93)90247-U
Deletion of transketolase triggers a stringent metabolic response in promastigotes and loss of virulence in amastigotes of Leishmania mexicana 10.1371/journal.ppat.1006953
The elimination of human African trypanosomiasis is in sight: Report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis 10.1371/journal.pntd.0006925
Gluconeogenesis using glycerol as a substrate in bloodstream-form Trypanosoma brucei 10.1371/journal.ppat.1007475
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation 10.1101/19001594
Protozoan persister-like cells and drug treatment failure 10.1038/s41579-019-0238-x
Pharma to farmer: field challenges of optimizing trypanocide use in African animal trypanosomiasis 10.1016/
Rónán Daly
Daly Rónán
ORCID: 0000-0002-1275-6820
Metabolomics Identifies Multiple Candidate Biomarkers to Diagnose and Stage Human African Trypanosomiasis 10.1371/journal.pntd.0005140
MetaboCraft: building a Minecraft plugin for metabolomics 10.1093/bioinformatics/bty102
ShinyKGode: an interactive application for ODE parameter inference using gradient matching 10.1093/bioinformatics/bty089
Plasma Itaconate elevation following successful cDMARD treatment in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation 10.1101/19001594
Changing environments and genetic variation: natural variation in inbreeding does not compromise short-term physiological responses 10.1098/rspb.2019.2109
In Silico Optimization of Mass Spectrometry Fragmentation Strategies in Metabolomics 10.1101/744227
Decomposing metabolite set activity levels with PALS 10.1101/2020.06.07.138974
Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage Activation 10.3390/metabo10060241
Rapid Development of Improved Data-dependent Acquisition Strategies 10.1101/2020.09.11.293092
Ranking Metabolite Sets by Their Activity Levels 10.3390/metabo11020103
R package for statistical inference in dynamical systems using kernel based gradient matching: KGode 10.1007/s00180-020-01014-x
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection 10.1038/s41378-021-00243-4
High sodium intake, glomerular hyperfiltration, and protein catabolism in patients with essential hypertension 10.1093/cvr/cvaa205
Rapid Development of Improved Data-Dependent Acquisition Strategies 10.1021/acs.analchem.0c03895
Ranking microbial metabolomic and genomic links in the NPLinker framework using complementary scoring functions 10.1371/journal.pcbi.1008920